Astria Therapeutics (ATXS) Competitors $9.37 -0.72 (-7.14%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATXS vs. SLDB, NEOS, ICCC, FRLN, CORV, WVE, AKRO, EVO, HRMY, and CNTAShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Solid Biosciences (SLDB), Neos Therapeutics (NEOS), ImmuCell (ICCC), Freeline Therapeutics (FRLN), Correvio Pharma (CORV), Wave Life Sciences (WVE), Akero Therapeutics (AKRO), Evotec (EVO), Harmony Biosciences (HRMY), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "medical" sector. Astria Therapeutics vs. Solid Biosciences Neos Therapeutics ImmuCell Freeline Therapeutics Correvio Pharma Wave Life Sciences Akero Therapeutics Evotec Harmony Biosciences Centessa Pharmaceuticals Astria Therapeutics (NASDAQ:ATXS) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking. Which has more risk & volatility, ATXS or SLDB? Astria Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Is ATXS or SLDB more profitable? Astria Therapeutics' return on equity of -43.58% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -43.58% -29.36% Solid Biosciences N/A -58.75%-47.84% Does the media refer more to ATXS or SLDB? In the previous week, Solid Biosciences had 13 more articles in the media than Astria Therapeutics. MarketBeat recorded 26 mentions for Solid Biosciences and 13 mentions for Astria Therapeutics. Astria Therapeutics' average media sentiment score of 0.69 beat Solid Biosciences' score of -0.06 indicating that Astria Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astria Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in ATXS or SLDB? 99.0% of Astria Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 2.9% of Astria Therapeutics shares are owned by insiders. Comparatively, 13.6% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in ATXS or SLDB? Astria Therapeutics received 300 more outperform votes than Solid Biosciences when rated by MarketBeat users. Likewise, 72.87% of users gave Astria Therapeutics an outperform vote while only 68.39% of users gave Solid Biosciences an outperform vote. CompanyUnderperformOutperformAstria TherapeuticsOutperform Votes56472.87% Underperform Votes21027.13% Solid BiosciencesOutperform Votes26468.39% Underperform Votes12231.61% Which has better valuation & earnings, ATXS or SLDB? Astria Therapeutics has higher earnings, but lower revenue than Solid Biosciences. Astria Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$72.89M-$2.09-4.48Solid Biosciences$8.09M23.96-$96.01M-$3.04-1.60 Do analysts prefer ATXS or SLDB? Astria Therapeutics presently has a consensus target price of $25.60, indicating a potential upside of 173.21%. Solid Biosciences has a consensus target price of $15.14, indicating a potential upside of 212.22%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Solid Biosciences is more favorable than Astria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 SummarySolid Biosciences beats Astria Therapeutics on 9 of the 17 factors compared between the two stocks. Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$528.79M$6.53B$5.15B$8.74BDividend YieldN/A8.15%5.18%4.08%P/E Ratio-4.484.4062.6013.00Price / SalesN/A377.651,277.9088.72Price / CashN/A51.2139.7935.27Price / Book2.159.636.455.92Net Income-$72.89M$154.43M$119.73M$225.73M7 Day Performance-20.73%-9.46%-5.13%-1.34%1 Month Performance-20.32%-7.27%-2.71%1.15%1 Year Performance111.99%28.13%31.08%24.02% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics1.6358 of 5 stars$9.37-7.1%$25.60+173.2%+107.3%$528.79MN/A-4.4830Analyst ForecastAnalyst RevisionNews CoverageSLDBSolid Biosciences3.5385 of 5 stars$4.85-8.7%$15.14+212.2%+78.3%$193.78M$8.09M-1.60100Analyst ForecastAnalyst RevisionNews CoverageNEOSNeos TherapeuticsN/A$1.15flatN/A+0.0%$57.22M$64.65M-2.61213High Trading VolumeICCCImmuCell0.5999 of 5 stars$3.61+0.3%N/A-22.7%$32.17M$17.47M-7.2275Short Interest ↓News CoverageFRLNFreeline TherapeuticsN/A$6.48flat$6.50+0.3%N/A$28.12MN/A-1.16152CORVCorrevio PharmaN/A$0.42flatN/AN/A$27.80M$32.63M-0.51133WVEWave Life Sciences4.8718 of 5 stars$13.67-8.9%$21.89+60.1%+149.0%$2.08B$113.31M-12.32240Analyst ForecastInsider SellingShort Interest ↑Analyst RevisionNews CoverageAKROAkero Therapeutics4.0326 of 5 stars$28.09-5.6%$43.20+53.8%+94.5%$1.96BN/A-7.4930Earnings ReportShort Interest ↓Analyst RevisionNews CoverageEVOEvotec1.0235 of 5 stars$5.44+6.7%$5.93+9.1%-44.7%$1.93B$845.74M0.005,061Short Interest ↓News CoverageGap UpHigh Trading VolumeHRMYHarmony Biosciences4.8494 of 5 stars$33.22+0.7%$47.00+41.5%+28.5%$1.89B$582.02M15.74200Short Interest ↓CNTACentessa Pharmaceuticals3.8575 of 5 stars$16.00-8.6%$25.83+61.5%+129.2%$1.81B$6.85M-10.4672Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage Related Companies and Tools Related Companies Solid Biosciences Competitors Neos Therapeutics Competitors ImmuCell Competitors Freeline Therapeutics Competitors Correvio Pharma Competitors Wave Life Sciences Competitors Akero Therapeutics Competitors Evotec Competitors Harmony Biosciences Competitors Centessa Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATXS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXS Stock Alerts